The innovation of new therapies to combat multidrug-resistant (MDR) bacteria is being 28 outpaced by the continued rise of MDR bacterial infections. Of particular concern are hospital-29 acquired infections (HAIs) recalcitrant to antibiotic therapies. The Gram-positive intestinal 30 pathobiont Enterococcus faecalis is associated with HAIs and some strains are MDR. Therefore, 31 novel strategies to control E. faecalis populations are needed. We previously characterized an E. 32
Disruption of the intestinal microbiota can predispose individuals to infection by opportunistic 80 pathogens (1, 2) . Antibiotics facilitate such disturbances leading to the development of hospital-81 acquired infections (HAIs) (3, 4) . Enterococcus faecalis, a normal constituent of the healthy 82 human intestinal microbiota and historically used in probiotics and during food fermentation, is 83 now a leading cause of HAIs (5) (6) (7) . E. faecalis is an adept opportunist that can proliferate in the 84 dysbiotic intestine following antibiotic perturbation (8) . Antibiotic-resistant clinical isolates of E. 85 faecalis typically possess expanded genomes compared to susceptible isolates due to the 86
Results 145
Delivery of CRISPR-Cas9 effectively removes antibiotic resistance in vitro by targeting 146
plasmid-borne resistance genes 147
To assess the ability of CRISPR-Cas9 to target and remove antibiotic resistance in E. faecalis, 148
we modified the PRP pPD1 by introducing the cas9 gene and a CRISPR guide RNA under the 149 control of the constitutive bacA promoter ( Fig. 1A and S1 ). To facilitate detection of the plasmid 150 we included a chloramphenicol resistance marker (cat) for selection. We generated two pPD1 151 derivatives, referred to as pKH88[sp-tetM] and pKH88[sp-ermB], which carry guide RNAs that 152 target the enterococcal tetM and ermB genes conferring tetracycline and erythromycin resistance, 153 respectively. These plasmids retain pheromone response functions and bac-21 bacteriocin 154 production ( Fig. 1A) . 155 7 PRPs are vehicles for the transmission of antibiotic resistance genes in E. faecalis populations 157 (30), thus we first assessed the ability of our engineered pPD1 derivatives to eliminate antibiotic 158 resistance genes present on other PRPs. We reasoned that bacteriocin production by pKH88 159 derivatives would promote maintenance of these plasmids in enterococcal populations. The donor 160 strain used in these experiments was E. faecalis CK135 and the recipient was E. faecalis OG1SSp 161 possessing either pAM771 which carries the erythromycin resistance gene ermB or pCF10 which 162 carries the tetracycline resistance gene tetM (Fig. 1B) . Both CK135 and OG1SSp are isogenic 163 derivatives of the human oral commensal isolate OG1 (43). We mixed donors and recipients and 164 plated them on Brain Heart Infusion (BHI) agar. After overnight growth we recovered the biofilm 165 and enumerated colony forming units (CFU) of the different cell types (passage 0 in Fig. 1C and 166 1D). We observed a significant reduction in the number of erythromycin-and tetracycline-resistant 167 transconjugants only when recipient cells received a pKH88 derivative encoding a cognate 168 CRISPR guide (Fig. 1C and 1D ). Non-cognate guides were ineffective at reducing antibiotic 169 resistance. This loss of antibiotic resistance was maintained after growth of the community in To determine whether the pKH88 plasmids would be effective against MDR E. faecalis, we 176 used pKH88[sp-ermB] to target ermB in E. faecalis V583 ( Fig. 2A) , a vancomycin-resistant 177 hospital-adapted isolate (44). V583 ermB is encoded on the plasmid pTEF1, and V583 does not 178 encode a tetM gene (10, 45). Initially, we observed poor conjugation frequencies of pKH88 179 derivatives into V583 when using CK135 as the donor ( Fig. S2A and S2B ). E. faecalis V583 180 encodes a Type IV restriction endonuclease that restricts entry of 5-methylcytosine-modified DNA 8 that this barrier could account for the reduced dissemination of pKH88 to E. faecalis V583. 183 Therefore, we utilized the E. faecalis OG1 variant strain OG1RF deleted for a 5-methylcytosine 184 DNA methyltransferase (ΔEfaRFI) as the donor strain. This strain cannot methylate plasmid DNA 185 and the plasmid will not be cleaved by the recipient cell following conjugation (47). We observed 186 that delivery of pKH88[sp-ermB] from E. faecalis OG1RF(ΔEfaRFI) to E. faecalis V583 decreased 187 total erythromycin resistance in the population (Fig. 2B ). In addition, E. faecalis V583 did not 188 tolerate CRISPR cleavage of ermB on pTEF1, indicated by a reduction in viable E. faecalis V583 189 cells ( Fig. 2B ) and which is consistent with our previous findings (26 Fig. S4A and S4B ). We attribute this gradual reduction in the recipient population to competitive 205 killing by bacteriocin-producing donors as previously described for pPD1 carrying E. faecalis (29), 206 and/or competition from the reemerging native microbiota that was initially displaced by the 9 resistant OG1SSp) appeared two days post-colonization of the donor strains for both the 209 pKH88[sp-ermB] and pKH88[sp-tetM] groups ( Fig. S4C ). However, the initial frequency of 210 transconjugants per recipient reached only ~10 -5 , indicating that overall conjugation frequency 211 was relatively low (Fig. 3A ). This was followed by a gradual increase in the transconjugant to 212 recipient ratio, approaching 1:1 (Fig. 3A) , as the total recipient population decreased over time 213 ( Fig. S4A ). This suggests that the initial transconjugant population remains fixed due to a pKH88 214 bacteriocin-mediated fitness advantage upon restoration of the indigenous microbiota. 215
216
Although there appeared to be a trend of reduced erythromycin resistance within the recipient 217 population for the pKH88[sp-ermB] group, no statistically significant reduction in the number of 218 erythromycin-resistant recipients compared to the total recipient population was observed in the 219 pKH88[sp-ermB] targeting group (Fig. 4A ). Similarly no significant difference in the erythromycin 220 resistant recipients compared to total recipients was observed for the pKH88[sp-tetM] non-221 targeting group (Fig. 4B ). However, to our surprise, the difference in erythromycin-resistant 222 recipients between the pKH88[sp-ermB] and pKH88[sp-tetM] groups was considerably less than 223 the difference between the total erythromycin resistant intestinal E. faecalis, which includes both 224 donors and recipients. The magnitude of this difference was ~3 log by the end of the experiment 225 ( Fig 5A) . This indicated that there was likely a substantial amount of conjugation by pAM771 into 226 the donor population. Indeed, in as little as two days, donors acquired erythromycin resistance, 227 but only in the pKH88[sp-tetM] non-targeting group (Fig. 5B ). These data indicate that E. faecalis 228 CK135(pKH88[sp-tetM]) donors are susceptible to counter-conjugation of pAM771 from recipients 229 but that CK135(pKH88[sp-ermB]) donors are immune, presumably due to CRISPR-Cas targeting 230 of ermB on pAM771 upon counter-conjugation. We conclude that our CRISPR antimicrobial 231 dramatically reduces the prevalence of a targeted conjugative plasmid within the input E. faecalis 232 population, likely through a multifactorial mechanism involving a bacteriocin-dependent Despite sustained high density colonization of both donors and recipients, the total number of 246 transconjugants was similar to those observed in the antibiotic dysbiosis model ( Fig. S5C and 247 S4C) but the transconjugant per recipient ratio remained stably low at 10 -5 ( Fig. 3B ). Sustained 248 high recipient density indicated that the apparent competitive advantage possessed by pKH88-249 containing donors via bac-21 does not manifest in gnotobiotic mice. These data suggest that even 250 with prolonged high densities of both donors and recipients in the absence of microbial 251 complexity, there may be biogeographical barriers that restrict the dissemination of pKH88 252 derivatives. This also implies that the competitive advantage possessed by the donor is most 253 prevalent in the presence of the microbiota, and therefore some degree of microbial complexity 254 is likely necessary for the functionality of our CRISPR-Cas antimicrobial. Interestingly, similar to 255 observations in the antibiotic dysbiosis model, pKH88 donors acquired erythromycin resistance, 256 but only in the pKH88[sp-tetM] non-targeting group (Fig. 5C ). 257
258
These results demonstrate that our engineered CRISPR-Cas antimicrobial is a robust barrier 259 to in vivo plasmid acquisition and reduces the in vivo prevalence of a specifically targeted drug 260 resistance trait. From a technological viewpoint this is the ideal situation of a prospective 261 "probiotic" donor; a strain that can effectively disseminate a CRISPR targeting plasmid while being 262 protected from acquisition of undesirable traits. 263
264

CRISPR-Cas antimicrobial prevents antibiotic-mediated intestinal expansion of 265
transconjugants. 266
A hallmark of enterococcal intestinal colonization is its ability to expand its population upon 267 antibiotic perturbation of the indigenous microbiota (4, 25) . This antibiotic-mediated expansion is 268 attributed to both intrinsic and acquired antibiotic resistance. To determine the ability of our 269 CRISPR-Cas antimicrobial to minimize the outgrowth of erythromycin resistant E. faecalis in the 270 intestine following antibiotic therapy, we utilized both our antibiotic dysbiosis and gnotobiotic 271 mouse models. We treated the mice 27 days post co-colonization with a single 40 This study presents a strategy for the delivery of a CRISPR-based antimicrobial that targets 306 antibiotic-resistant E. faecalis. We show that this conjugative antimicrobial significantly reduces 307 antibiotic resistance from in vitro and in vivo enterococcal communities in the absence of 308 externally applied selection for donor strains. Our approach for the delivery of a CRISPR-Cas 309 antimicrobial differs from studies which employed either transformable plasmids or phages for the 310 recognition and delivery to target cells (18-21). Although these studies provided the foundation 311 for the use of CRISPR antimicrobial activity against bacteria, limitations were noted. In the case 13 of phage-mediated CRISPR antimicrobial dissemination, this technique suffered from incomplete 313 phage dissemination. This scenario is expected due to selective pressures imposed on bacteria 314 by phages during infection, including receptor mutations (22-25). Such issues have recently been 315 addressed using multi-phage delivery systems or by co-opting phage particles for the delivery of 316 CRISPR-Cas targeting modules embedded within mobilizable genome islands (49, 50) . Although 317 the use of a phage-based delivery system for E. faecalis should be possible, enterococcal phage 318 biology is understudied and limited information exists concerning phage host ranges and genetics. 319 Therefore, we chose to engineer a PRP for the dissemination of an E. faecalis-specific CRISPR-320
Cas antimicrobial for several reasons. First, the conditions governing PRP regulation have been 321 extensively studied. Second, PRPs are specific for E. faecalis. Third, PRPs achieve high 322 conjugation rates and can be genetically modified to diversify host tropism by altering pheromone 323 responsiveness. Fourth, PRPs are stably maintained and disseminate in the absence of selection 324 (51, 52). 325
326
The intestine is a reservoir for MDR E. faecalis, and E. faecalis infections often follow 327 exposure to broad spectrum antibiotics. We applied our CRISPR-Cas antimicrobial method for 328 the removal of an antibiotic resistance trait from intestinal E. faecalis. The mouse models of 329 intestinal colonization used were designed to mimic enterococcal overgrowth in the human 330 intestine following antibiotic therapy (3, 4) . Antibiotics disrupt the intestinal microbiota, allowing 331 antibiotic-resistant enterococci to become the dominant colonizer. In our study, we used E. 332 faecalis donor strains for the conjugative delivery of CRISPR-Cas to remove erythromycin 333 resistance from an abundant intestinal E. faecalis target population. The conjugative transfer of 334 an ermB-specific CRISPR-Cas targeting system into recipient E. faecalis cells showed little to no 335 reduction in erythromycin resistance from the total intestinal E. faecalis recipient population. 336
indicates that, although the frequency of conjugation was low compared to the total available 339 recipient population and not as robust as in vitro conjugation frequencies, the specificity of our 340 CRIPSR-Cas targeting system in the intestine was absolute. If successful conjugation occurs, 341 there is complete loss of erythromycin resistance. In addition, we observed that donors carrying 342 a cognate CRISPR antimicrobial plasmid were protected from acquisition of erythromycin 343 resistance from recipients. This is an important feature of our deliverable system since the 344 transmission of undesirable target traits to donor cells would impede the usefulness of such a 345 delivery strategy within complex microbial environments. The discovery that E. faecalis donor 346 cells carrying the CRISPR-Cas antimicrobial are immunized against the acquisition of antibiotic 347 resistance suggests that donors could be used as a probiotic. These probiotic E. faecalis cells 348 would be protected from the acquisition of antibiotic resistance traits and could pre-emptively 349 occupy the intestine to outcompete or inhibit invading multidrug resistant strains. to recipient cells (54). This is due to the production of inhibitory self-signaling peptides produced 361 by the donors that compete with recipient pheromones and reduce conjugation frequencies. 362 be more efficient at a precise density of donors, recipients, or both, which may require future 365 optimization for effective plasmid delivery. 366
367
Moving forward, improvements to our current system are justified if an engineered conjugative 368 CRISPR antimicrobial is to be clinically effective for precision removal of antibiotic resistance 369 genes in E. faecalis or other MDR bacteria. Modifications include multiplexing CRISPR guide 370 RNAs to target different resistance genes and/or the same genes at multiple sites, as well as 371 increasing the overall conjugation frequency by altering PRP regulation, dosing of donor strains, 372 or the plasmid replicon itself. Theoretically, resistance to bac-21 could compromise the efficacy 373 of our system, and future iterations should utilize alternative bacteriocins as well as bacteriocin-374 free constructs. In this study we focused on targeting antibiotic resistance that resides on 375 plasmids. However, many E. faecalis antibiotic resistance genes are chromosomally encoded. 376
Future iterations of this system should also be engineered for the specific targeting of 377 chromosomal antibiotic resistance genes. Recently we showed that CRISPR-Cas targeting of the 378 vanB locus on the E. faecalis V583 chromosome is lethal (40) . Targeting chromosomal antibiotic 379 resistance genes could have the added feature of bacterial lethality. Such a strategy may be 380 preferable depending on whether the intended use of the CRISPR-Cas antimicrobial is for 381 reshaping the microbiota or for targeting drug resistant strains during infection. 382 383
Our model system has relied on laboratory-domesticated strains of E. faecalis OG1 (43), it 384 will be imperative to determine the efficacy of this system against more "wild" clinical isolates 385 which are the intended targets of such a therapy. For safe and effective delivery of the CRISPR 386 antimicrobial in the clinic, the use of an attenuated E. faecalis strain or a related member of the 387 Lactobacillales approved for probiotic use would be essential. Finally, this system could be 388 adapted for the targeted removal of antibiotic resistance from bacteria other than E. faecalis. Isolation Kit (Qiagen). Antibiotics were used at the following concentrations: chloramphenicol, 15 408 μg/ml; streptomycin, 500 μg/ml; spectinomycin, 500 μg/ml; vancomycin, 10 μg/ml; erythromycin, 409 50 μg/ml; rifampicin, 50 μg/ml; fusidic acid, 25 μg/ml; tetracycline, 10 μg/ml. 410 411
Strain and plasmid construction 412
All strains used in this study can be found in Table S1 . The donor strain used for competition 413 experiments was a rifampicin and fusidic acid-resistant derivative of CK135 (57). All plasmids 414 used in this study can be found in Table S2 . Fragments obtained from the plasmids pHA101 (58), polymerase and assembled using NEB HiFi DNA Assembly Master Mix (New England Biolabs). 417
For simplicity, assembly of the CRISPR-targeting construct (PbacA-cas9-cat-guide RNA) was 418 divided into two steps. First, PbacAcas9 was introduced into pPD1 by homologous recombination. 419
Then the cat gene from pKH12 and the PbacA-driven CRISPR guide RNA was integrated 420 downstream of PbacA-cas9. Following the generation of this construct, we discovered that the first 421 integration site obstructed the pheromone response, therefore the entire engineered region (PbacA-422 cas9-cat-guide RNA) was amplified as one fragment and integrated into native pPD1 between 423 orfs ppd4 and ppd5 using the integration plasmid pCOP88 (Fig. S1 ). The modified pPD1 424 derivatives are designated as pKH88[sp-tetM] and pKH88[sp-ermB], which target tetM or ermB 425 respectively. Primer sequences are listed in Table S3 . For the antibiotic dysbiosis model, 7 days prior to colonization, 6-8 week old C57BL6/J mice 442 were gavaged with 150 μL of an antibiotic cocktail (streptomycin 1 mg/mL, gentamicin 1 mg/mL, 443 erythromycin 200 μg/mL) and given a water bottle ad libitum with the same antibiotic cocktail for 444 6 days following the initial gavage. 24 hours prior to colonization with recipient E. faecalis, 445 antibiotic water was removed and replaced with standard sterile reverse osmosis water. Donor 446 and recipient strains were cultured overnight in BHI and mice were gavaged with ~10 9 
